✦ LIBER ✦

Green Tea Polyphenols and Cancer Chemoprevention: Multiple Mechanisms and Endpoints for Phase II Trials

✍ Scribed by Susan B. Moyers; Nagi B. Kumar

Book ID: 111435536
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 224 KB
Volume: 62
Category: Article
ISSN: 0029-6643
DOI: 10.1111/j.1753-4887.2004.tb00041.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Strategies for phase II cancer chemoprev

Strategies for phase II cancer chemoprevention trials: Cervix, endometrium, and ovary

✍ Dr. Gary J. Kelloff; Charles W. Boone; James A. Crowell; Susan G. Nayfield; Erne 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 782 KB

Well-designed and conducted Phase 11 clinical trials are very important to cancer chemoprevention drug development. Three critical aspects govern the design and conduct of these trials-wellcharacterized agents, suitable cohorts, and reliable biomarkers for measuring efficacy that can serve as surrog

Subjects and recruitment strategies for

Subjects and recruitment strategies for a short-term phase II chemoprevention trial of breast cancer using surrogate endpoint biomarkers

✍ Victor G. Vogel 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Progression of breast neoplasia is characterized by a variety of causal and nonspecific molecular, karyotypic, and cellular level genetic alterations. These include allelic losses, chromosomal rearrangements, and aneusomies, as well as widely divergent clonal DNA content aberrations. Establishment o

Challenges and potential solutions to me

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer

✍ Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E. Spiess; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 318 KB

Phase II randomized trial of bevacizumab

Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial

✍ George Somlo; Ashkan Lashkari; William Bellamy; Todd M. Zimmerman; Joseph M. Tus 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

1187 Molecular Mechanism of Synergistic

1187 Molecular Mechanism of Synergistic Anti-tumor Activity by the Combination of Natural Compounds Green Tea (-)Epigallocathetin-3-gallate (EGCG) and Resveratrol for Potential Chemoprevention in Head and Neck Cancer (HNC)

✍ Shin, D.M.; Amin, A.R.M.; Wang, D.; Rahman, M.A.; Nannapaneni, S.; Khuri, F.R.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Edatrexate (10-ethyl-deaza-aminopterin)

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma : Sequential Phase II trials by the Cancer and Leukemia Group B

✍ Hedy L. Kindler; Chandra P. Belani; James E. Herndon II; Nicholas J. Vogelzang; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

The Cancer and Leukemia Group B (CALGB) conducted sequential Phase II multicenter trials to evaluate the activity of edatrexate alone (E) or with leucovorin rescue (EL) in patients with malignant pleural mesothelioma (CALGB Protocol 9131).